BioChaperone Lispro: Phase I data

A 4-way crossover, double-blind Phase I trial in 26 healthy volunteers under euglycemic clamp showed that 0.2 U/kg doses of subcutaneous BioChaperone Lispro U200 retained the ultra-rapid profile of 0....